Evidence map›Paper›PMID 24816265›Full record

ArticleActa biomaterialia2014

Post-transcriptional regulation in osteoblasts using localized delivery of miR-29a inhibitor from nanofibers to enhance extracellular matrix deposition.

Eric N James, Anne M Delany, Lakshmi S Nair

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biomaterialia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 58 citations in OpenAlex.

  1. Engineering Nanoparticles and Bioscaffolds for Targeted microRNA Delivery in Cardiovascular Regeneration-A Comprehensive Review.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. MicroRNAs and Bone Regeneration.Current genomics · 2015
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Eric N JamesDepartment of Orthopedic Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA; Institute for Regenerative Engineering, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA.
Anne M DelanyCenter for Molecular Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA.
Lakshmi S NairDepartment of Orthopedic Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA; Institute for Regenerative Engineering, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA; Department of Materials Science and Engineering and Department of Biomedical Engineering, University of Connecticut Storrs, CT 06268, USA. Electronic address: nair@uchc.edu.
UConn Health · US

Funding

Function and Regulation of Osteonectin in BoneR01AR044877 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI DELANY, ANNE M · 2003 to 2013
$2.6M
Injectable Anabolic Biomaterials for Bone RegenerationR03AR061575 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI NAIR, LAKSHMI S · 2012 to 2014
$345k
NIAMS NIH HHS AR061575NIAMS NIH HHS R01 AR044877NIAMS NIH HHS R03 AR061575PHS HHS R044877
6 · The paper itself

Abstract

MicroRNAs are important post-transcriptional regulators of skeletal biology, and miRNA-based therapeutics have the potential to aid bone repair. However, efficient tools for delivering miRNA mimics or inhibitors to specific target tissues are limited. Polymeric nanofibers closely mimic natural extracellular matrix (ECM) morphology, and are attractive candidates for supporting delivery of cells and bone-anabolic reagents. It is hypothesized that gelatin nanofibers could be used for the localized transient delivery of miRNA-based therapeutics, using miR-29a inhibitor as a prototype to increase ECM deposition. miR-29 family members are negative regulators of ECM synthesis, targeting the mRNAs of selected collagens and osteonectin/SPARC. Inhibiting miR-29 activity may therefore increase ECM production by cells. miR-29a inhibitor-loaded gelatin nanofibers, prepared by electrospinning, demonstrated continuous release of miRNA inhibitor over 72h. Pre-osteoblastic murine MC3T3-E1 cell line seeded on miR-29a inhibitor-loaded nanofibers synthesized more osteonectin, indicating efficient inhibitor delivery. These cells also displayed increased Igf1 and Tgfb1 mRNA. Moreover, primary bone marrow stromal cells from transgenic pOBCol3.6cyan reporter mice, grown on miR-29a inhibitor scaffolds, displayed increased col3.6 cyan expression as well as collagen production. This study demonstrates that ECM mimicking nanostructured scaffolds, in conjunction with bioactive miRNA-based therapeutics, may serve as a novel platform for developing biologically active localized cell delivery systems.

Indexed as

AnimalsBALB 3T3 CellsExtracellular MatrixGene Expression RegulationMiceMicroRNAsNanocapsulesNanofibersOligonucleotidesOsteoblastsRNA Processing, Post-TranscriptionalMicroRNAsMIRN29 microRNA, mouseNanocapsulesOligonucleotidesBoneExtracellular matrixmicroRNANanofibersOsteonectin

Identifiers

PMID24816265
PMCPMC4114157
OpenAlexW2063622409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.